Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) and NeurAxis (NASDAQ:NRXS – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.
Valuation & Earnings
This table compares Fresenius SE & Co. and NeurAxis”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fresenius SE & Co. | $25.87 billion | 1.15 | $1.43 billion | $0.79 | 16.77 |
| NeurAxis | $5.32 million | 17.98 | -$14.63 million | ($0.78) | -9.76 |
Volatility & Risk
Fresenius SE & Co. has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, NeurAxis has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Fresenius SE & Co. and NeurAxis, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fresenius SE & Co. | 0 | 0 | 3 | 0 | 3.00 |
| NeurAxis | 0 | 0 | 1 | 0 | 3.00 |
NeurAxis has a consensus price target of $13.00, suggesting a potential upside of 70.83%. Given NeurAxis’ higher probable upside, analysts plainly believe NeurAxis is more favorable than Fresenius SE & Co..
Profitability
This table compares Fresenius SE & Co. and NeurAxis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fresenius SE & Co. | 6.67% | 10.25% | 4.87% |
| NeurAxis | -492.76% | N/A | -641.25% |
Institutional & Insider Ownership
11.8% of NeurAxis shares are owned by institutional investors. 21.1% of NeurAxis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Fresenius SE & Co. beats NeurAxis on 8 of the 13 factors compared between the two stocks.
About Fresenius SE & Co.
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
About NeurAxis
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
Receive News & Ratings for Fresenius SE & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
